Shaun P. Tolan
Birkenhead, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial.
Journal: The Lancet. Oncology
Published: December 20, 2024
Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer.
Journal: The New England journal of medicine
Published: October 16, 2024
Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised Trial.
Journal: European urology
Published: April 18, 2024
Developing and validating a simple urethra surrogate model to facilitate dosimetric analysis to predict genitourinary toxicity.
Journal: Clinical and translational radiation oncology
Published: January 17, 2024
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial.
Journal: The Lancet. Oncology
Published: May 31, 2022
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 10, 2021
Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience.
Journal: The breast journal
Published: September 26, 2021
Using Real-world Data to Define a Validated Nomogram for Advanced Bladder Cancer Patients Who Respond to Immunotherapy.
Journal: Clinical oncology (Royal College of Radiologists (Great Britain))
Published: September 17, 2021
Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 19, 2020
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 28, 2019
Last Updated: 09/26/2026